ANXA5 and melanoma: Given that pharmacological activation of TRPV4 could inhibit cell viability, to assess the lethality of GSK1016790A to melanoma cell lines, A375 cells were treated with GSK1016790A at various concentrations for 24 h and then analysed by flow cytometry with FITC conjugated Annexin V and PI.